Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

3 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness and safety of a treatment called AP707 for individuals experiencing chronic pain due to diabetic polyneuropathy. Diabetic polyneuropathy is a condition that affects the nerves, often leading to persistent pain. The trial aims to evaluate how well AP707 works as an additional treatment for managing this type of pain.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will be conducted over several weeks, with regular assessments to monitor changes in pain levels and overall well-being. The goal is to determine if AP707 can provide significant relief from pain compared to the placebo.

Throughout the trial, participants will be asked to report their pain levels and any changes in their condition. The study will also track any side effects or adverse events to ensure the safety of the treatment. By the end of the study, researchers hope to gather valuable information about the potential benefits of AP707 for those suffering from chronic pain due to diabetic polyneuropathy.

1 beginning of the trial

Upon joining the study, you will be asked to provide a signed and dated informed consent form. This confirms your understanding and agreement to participate in the trial.

You will undergo an initial assessment to confirm eligibility, which includes verifying that you have experienced chronic pain due to diabetic polyneuropathy for at least three months and that your pain intensity is moderate to severe.

2 baseline assessment

A baseline assessment will be conducted to establish your current pain levels and overall health status. This includes completing questionnaires such as the Numeric Rating Scale (NRS) for pain and the Neuropathic Pain Symptom Inventory (NPSI).

You will also be asked to complete additional questionnaires to assess psychological distress, quality of life, and sleep quality.

3 treatment phase 1

You will begin the first treatment phase, which lasts for 14 weeks. During this time, you will receive either the study medication AP707 or a placebo. The medication is administered as a sublingual spray, which means it is sprayed under the tongue.

Your pain levels and other health indicators will be monitored regularly through scheduled visits and questionnaires.

4 evaluation at week 14

At the end of week 14, your pain levels will be reassessed using the Numeric Rating Scale (NRS) and other questionnaires. This evaluation will help determine the effectiveness of the treatment during the first phase.

You will continue to receive either the study medication or placebo as the trial progresses into the next phase.

5 treatment phase 2

The second treatment phase extends from week 15 to week 26. You will continue with the same treatment regimen as in the first phase.

Regular assessments will be conducted to monitor any changes in your pain levels and overall health.

6 evaluation at week 26

At the end of week 26, another evaluation will be conducted to assess changes in your pain levels and other health indicators.

This evaluation will help determine the effectiveness of the treatment during the second phase.

7 treatment phase 3

The third and final treatment phase lasts from week 27 to week 52. You will continue with the same treatment regimen.

Your health and pain levels will be monitored regularly through scheduled visits and questionnaires.

8 final evaluation at week 52

At the end of week 52, a final evaluation will be conducted to assess the overall effectiveness of the treatment throughout the trial.

This includes a comprehensive assessment of your pain levels, quality of life, psychological distress, and sleep quality.

Who Can Join the Study?

Signed and dated informed consent form.
Patients with chronic pain due to diabetic polyneuropathy for at least 3 months. Diabetic polyneuropathy is a type of nerve damage that can occur with diabetes, causing pain.
Female and male patients who are 18 years or older.
Patients with a life expectancy of more than 1 year.
Patients with optimized sCPT at the start of the study. sCPT refers to a specific treatment plan that is adjusted for the patient.
Willingness of both male and female patients to use reliable contraception during the study and for three months after taking the last study medication.
Good command of the German language to understand questionnaires in German.
Current moderate to severe pain with a pain intensity of 5 or more on the Numeric Rating Scale (NRS), which is a scale from 0 to 10 used to measure pain, indicating a need for further pain therapy.
Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with a score of 45 or less. This questionnaire helps assess certain symptoms related to pain.

Who Cannot Join the Study?

Patients who do not have chronic pain due to diabetic polyneuropathy cannot participate. This means the study is only for those who have long-lasting pain caused by nerve damage from diabetes.
Patients who are not within the specified age range cannot participate. The study is for adults only.
Patients who are part of a vulnerable population cannot participate. This means people who might need special protection or care are not included.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Medical University Of Vienna	Vienna	Austria
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany

Other Sites

Site Name	City	Country
Klinikum Wels-Grieskirchen GmbH	Wels	Austria
Noe LGA Gesundheit Region Mitte GmbH	Tulln An Der Donau	Austria
Algesiologikum MVZ GmbH	Munich	Germany
Ueberoertliche Berufsausuebungsgemeinschaft Schmerz Und Palliativzentrum Rhein Main GbR	Frankfurt	Germany
Schmerzzentrum Bocholt	Bocholt	Germany
Saarland University Hospital	Homburg	Germany
Katholisches Klinikum Bochum gGmbH	Bochum	Germany
Lmaorsijlgahkfqrzkupzepwwmqqovgtewlylnriwjb Kdpjq	Klagenfurt am Wörthersee	Austria
Uyqglkryjbweodcsawqjw Tlcsczfgx Azv	Tuebingen	Germany
Chhbrax Uuubsiqrxmgkbqibztxt Bqgmnk Khs	Berlin	Germany
Kqxhlw Utkdcpkflfkuplmakqird Gsut	Linz	Austria
Uxunypzfxzyr Lhedekj	Leipzig	Germany
Ktnkbiqs dnw Tsmjnfnggzk Ukbxjlcuracv Mgqtmutb (lsd Koeadxdvd	Munich	Germany
Uiebsubjnpejwqbpungll Edyrv Aew	Essen	Germany
Urvjosqjgeshyneedsrgh Srbgxhpguyejpmxtro Awg	Kiel	Germany
Oiryzajaystfyqahhcpd Guuaatzpkbpzrmwpmd Gqat	Steyr	Austria
Kukseq Orhnfkbc	Oberwart	Austria
Zzhduip ffh Szfohppl uuj Pjubfrjgrpmouomy Snkjuymr	Schwerte	Germany
Gfogxlehbwecwszdvgy Mpjtmtb Judupn ugy Aqxudzj Lyffxn	Borken	Germany
Swwxjpldmiflpzsntkxpono	Bad Vöslau	Austria
Szukmhhkiikqfb Gfccfph	Geldern	Germany
Mlqjbr Hfmvdvav Hvqeu Ulagcpijrdorciutkitd dgj Rehkjyepxmajvuex Bcbzvw	Herne	Germany
Uxavqdqorakyyqfzaqprp Gochcha urf Miwiuut Gsut	Marburg	Germany
Wivehhjqacrdtgi Kopsatzj Hgyzzd vyh Bsgpjl Gdky	Hagenow	Germany
Mgtzhjfsf Mja Gpbl	Neckarsulm	Germany
Sopxylxpnidhlblvo Fxkn Smmyfgndovysdip Benhvrvsddshlruusuqvcwgaima Gdw	Ulm	Germany
Ssotcrxvxodgeobraklvdb Bhus Mtrogb	Osnabrück	Germany
Bi Kejtweto Hirxhmg gakki	Hamburg	Germany
Bu Kmpejwgo Drghpzlm gcefo	Duisburg	Germany
Sijrrxrxhovcvx Ipitwuffufv	Burghausen	Germany
Puhipf Fre Npfljztxmp	Hoppegarten	Germany
Ppabzuummpdx Dlk Irimvxl &jckb Kizxxxqr	Munich	Germany
Kkfnbrnb Dmeqmdvd gexlk	Dortmund	Germany
Glkcaj Uaknzliqkx Fpuypuiop	Frankfurt	Germany
Ugnotlokdpchfjrxfeqmk Wglccwwjk Ach	Wuerzburg	Germany
Sixiilsnfccekrcp Kvbjlicz Vyaqqvfxhhkbrsesqqskdy Glyz	Villingen-Schwenningen	Germany
Blwocjmgxodxcuzblnqfispjqx Uxzegorfohnpwznwygaxi Bnoeqscntxdyq gecwp	Bochum	Germany
Syhebgnxswga Ksfwvzme Kyukflujw gzsqj	Karlsruhe	Germany
Upfigfxqukbuosxxdzegt Abndwbhd	Augsburg	Germany
Rexw Utlkrlmmsb	Bochum	Germany
Csnzbhyqyjdl Kebidpfp Ujjt gqpev	Unna	Germany
Bk Kafwxxwy Uigntrzysrwpoihif Baunqo ggpnt	Berlin	Germany
Hnnaummjbxqucgm Bsfnakthz	Gladbeck	Germany
Be Kqnkyb Tfwkmqyn	Tuebingen	Germany

Trial status

Country	Status	Recruitment Start
Austria	Not recruiting	01.09.2023
Germany	Not recruiting	01.09.2023

Trial locations

Investigated Drugs:

AP707 is a medication being tested to see how well it works and how well people can tolerate it when used as an additional treatment for chronic pain caused by diabetic polyneuropathy. Diabetic polyneuropathy is a condition where people with diabetes experience nerve damage, leading to pain, tingling, or numbness, usually in the feet and hands. AP707 is being studied to determine if it can help reduce this type of pain when added to the patient’s current treatment plan.

Investigated Diseases:

Diabetic Polyneuropathy – Diabetic polyneuropathy is a type of nerve damage that occurs in individuals with diabetes. It primarily affects the peripheral nerves, which are responsible for sensation and movement in the limbs. The disease progresses gradually, often starting with numbness or tingling in the feet and hands. Over time, it can lead to more severe symptoms such as burning pain, muscle weakness, and loss of reflexes. As the condition advances, it may affect balance and coordination, making walking difficult. The progression of symptoms can vary widely among individuals, depending on factors like blood sugar control and duration of diabetes.

Trial ID:

2022-500897-32-00

Protocol code:

DISCOVER_(PNP1)

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?